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Abstract
Background: A randomized trial of a pedometer-based intervention with weekly activity goals led to a modest
increase in step count among dialysis patients. In a secondary analysis, we investigated the effect of this
intervention on body composition.
Methods: Sixty dialysis patients were randomized to standard care or a 6-month program consisting of 3 months of
pedometers and weekly step count targets and 3months of post-intervention follow-up. We obtained bioelectrical
impedance spectroscopy (BIS) data on 54 of these patients (28 control, 26 intervention) and used linear mixed-
modeling (adjusted for sex and dialysis modality) to estimate differences in change in total-body muscle mass (TBMM)
adjusted for height2, fat mass (kg), and body mass index (BMI) (kg/m2) between control and intervention groups.
Results: The median age of participants was 57.5 years (53–66), and 76% were men. At baseline, there was no significant
difference between groups in age, BMI, race, or body composition, but there were more men in the intervention group.
After 3months, patients in the intervention group increased their average daily steps by 2414 (95% CI 1047, 3782) more
than controls (p < 0.001), but there were no significant differences in body composition. However, at 6months, participants
in the intervention had a significantly greater increase from baseline in TBMM of 0.7 kg/m2 (95% CI 0.3, 1.13), decrease in fat
mass (− 4.3 kg [95% CI -7.1, − 1.5]) and decrease in BMI (− 1.0 kg/m2 [95% CI -1.8, − 0.2]) relative to controls. In post-hoc
analysis, each increase of 1000 steps from 0 to 3months was associated with a 0.3 kg decrease in fat mass (95% CI 0.05, 0.5)
from 0 to 6months, but there was no dose-response relationship with TBMM/ht2 or BMI.
Conclusion: A pedometer-based intervention resulted in greater decreases in fat mass with relative preservation of muscle
mass, leading to a greater decrease in BMI over time compared with patients not in the intervention. These differences were
driven as much by worsening in the control group as by improvement in the intervention group. Step counts had a dose-
response relationship with decrease in fat mass.
Trial registration: ClinicalTrials.gov (NCT02623348). 02 December 2015.
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Background
Patients with end-stage renal disease (ESRD) on dialysis
have protein-energy imbalances [1] that can lead to
muscle wasting [2]. Lower muscle mass [3, 4] in dialysis
patients is associated with impairments in physical
function [5]. In addition, studies examining surrogates of
muscle mass [6, 7] as well as more accurate methods of
estimation of muscle mass such as bioelectrical impedance
spectroscopy (BIS) [8, 9] and dual-energy X-ray absorpti-
ometry (DXA) [10] suggest that lower muscle mass is as-
sociated with higher mortality in this population. Given
the increasing prevalence of obesity among ESRD patients
over the last decade [11], recent studies have examined
the presence of low muscle mass concurrent with high fat
mass in the dialysis population (sarcopenic obesity) and
found that sarcopenic obesity is associated with poor
physical performance and lower extremity function [12].
The Kidney Disease Outcomes Quality Initiative (K/
DOQI) guidelines recommend that all dialysis patients
should be encouraged to increase their physical activity
levels [13] based on evidence for the general population
and for individuals at high risk of cardiovascular disease
[14]. However, patients treated with dialysis are extremely
sedentary, with activity levels falling below those reported
by healthy sedentary individuals and by patients with other
chronic diseases [15–17], and these extremely low levels of
activity are associated with poor functional status and
higher mortality [18, 19]. Higher physical activity is associ-
ated with higher muscle mass in dialysis [20, 21], and prior
studies of exercise in dialysis patients have shown that vig-
orous exercise is associated with increase in muscle mass
[19, 22, 23], as well as improvement in physical functioning
[24–26]. However, the effect of a walking intervention on
measures of body composition has not been studied.
We conducted a 6-month randomized controlled trial
comparing 3 months of pedometers and weekly step
goals plus a 3-month post-intervention follow up with-
out counselling or pedometers with usual care among
patients treated with dialysis [27]. We used bioelectrical
impedance spectroscopy (BIS) to estimate body compos-
ition at 0, 3, and 6 months in order to ascertain whether
the pedometer-based walking intervention would result
in beneficial changes in body composition among pa-
tients on dialysis.
Methods
Full details of recruitment and enrollment into the Pe-
dometers and Exercise in Dialysis (PED) study have been
previously described, as well as full details of testing of
step counts [27].
Inclusion and exclusion criteria
Patients were enrolled from three San Francisco dialysis
clinics. Participants eligible for inclusion were ambulatory
patients aged ≥18 years who were treated with in-center
hemodialysis (HD) or any form of peritoneal dialysis (PD),
and had telephone access. Patients using wheelchairs or
scooters were excluded but those using a cane or other as-
sistive device were eligible. Patients with pacemakers, intra-
cardiac defibrillators, or metallic implants were excluded
from body composition analysis. All patients provided in-
formed consent to participate. The study was registered at
ClinicalTrials.gov (NCT02623348) and approved by the
UCSF Committee on Human Research (14–13,175).
Baseline testing
Participants were asked basic demographic information
such as race and ethnicity, and medical records were
reviewed for information about comorbid conditions, la-
boratory results, medications, and dialysis prescription.
Outcomes – body composition
Height was measured at baseline using a stadiometer.
Weight was recorded to the nearest 0.1 kg from an aver-
age of two weights taken prior to body composition test-
ing. Body-mass index (BMI) was derived from weight
divided by height in meters-squared.
Patients treated with HD were assessed immediately be-
fore a mid-week dialysis session, and patients on PD were
assessed at a usual clinic visit. For participants treated with
PD, weight was recorded after first subtracting the weight
from any in-dwelling dialysate. Body composition was esti-
mated non-invasively using multi-frequency whole-body
BIS performed with the SFB7 Body Composition Analyzer
(ImpediMed), which scans 256 frequencies between 4 and
1000 kHz. Patients were asked to sit in a reclining chair
and remain in that position for at least 5min. Patients
were asked to remove any jewelry, watches, or other metal
objects and to position themselves such that no part of
their body was making contact with or crossing over any
other part. After cleaning the skin with an alcohol wipe,
electrode pads were placed on their hands and feet and
leads attached in the appropriate configuration for meas-
uring resistance and reactance at various frequencies [28].
Total body muscle mass (TBMM) was estimated from
intracellular fluid volume according to the following equa-
tion: TBMM (in kg) = 9.52 + 0.331 x BIS-derived intracel-
lular volume (L) + 2.77 (male sex) + 0.180 x body weight
(kg) – 0.113 x age (years) [29]. TBMM was then indexed
to height in meters squared. Fat mass was estimated
through the SFB7’s internal protocol by subtracting total
body water (estimated using resistance extrapolated to in-
finite frequency) divided by 0.73 from body weight.
Baseline step counts
Step counts were measured using pedometers (Accusplit
AE120, Livermore, CA) [15, 30–32]. Patients were asked
to wear the pedometer at their waist during waking
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hours for 1 week and to record a diary of daily steps.
Study personnel obtained step counts by telephone or
in-person visit.
Randomization
Patients were randomly assigned to participate in a con-
trol group or our pedometer intervention program in a
balanced 1:1 distribution, stratified by dialysis modality.
We targeted enrollment of 48 HD patients and 12 PD
patients, with sample size chosen to provide 80% power
to detect an increase of 1000 steps or greater in the
intervention group compared to the control group des-
pite expected rates of dropout. Full details of
randomization have been published previously [27].
Intervention
The intervention consisted of providing pedometers and
weekly counselling sessions in which a member of the
study team called the participant each week at a sched-
uled time. Participants in the intervention group were
asked to continue wearing their pedometers after base-
line assessment and to record daily step counts for 3
months. During the weekly counselling session, partici-
pants relayed their diary of step counts from the prior
week to research personnel who then provided goals for
the upcoming week and advised about ways in which
participants could increase daily walking. The initial
counselling session was scheduled 1 week after baseline
assessment and randomization.
Participants in the intervention group were recom-
mended to increase their steps by 10% compared with the
prior week. For patients who had hospitalizations or other
events resulting in periods of reduced activity, we revised
their goals such that they would increase by 10% incre-
ments starting at their new “baseline” daily step level.
Patients in the control group were asked to return the
pedometers after relaying their record of steps from the
initial week of data collection and were not contacted
until the 3-month assessment. After the 3-month assess-
ment, pedometers were returned to study personnel by
both groups. We then measured step counts and body
composition again after an additional 3 months.
Statistical analysis
Patients’ baseline characteristics were summarized as
median (25th, 75th percentile) for continuous variables
or frequency and percentage for categorical variables.
For step counts specifically, we calculated average daily
steps over the week prior to each assessment for each
participant and reported the mean of those average daily
steps for each group. The primary outcome was
between-group difference in change in measures of body
composition at the end of the 6-month program. We
used mixed effects linear regression analyses to assess
changes at 6 months for TBMM, fat mass, and BMI. We
adjusted for the stratification factor (dialysis modality),
and sex, in each model. We also performed separate
analyses using mixed effects linear regression analysis as
above to assess changes from 0 to 3 months and from 3
to 6 months. In addition, we examined whether out-
comes differed among HD and PD patients in a pre-
specified subgroup analysis via an interaction test. We
performed post-hoc analyses using linear regression to
examine whether change in step counts from 0 to 3
months was associated with change in TBMM, fat mass,
or BMI over the course of the 6-month program.
Two-sided p-values < 0.05 were considered statistically
significant. Statistical analyses were performed using
Stata, version 14 (StataCorp, College Station, TX).
Results
Baseline characteristics
The first patient was enrolled in March 2016. We ceased
enrollment after randomizing a total of 60 patients (48
HD and 12 PD) per our study protocol and the final as-
sessment was performed in March 2018, concluding the
study. We were able to obtain body composition mea-
sures on 44 HD and 10 PD patients (Fig. 1). The median
age of patients with BIS data was 57.5 (53–66) and 76%
were men. Thirty-nine percent of participants were
black, 17% were white, and 40.7% had diabetes. Median
dialysis vintage was 3.3 (1.2–5.8) years. The racial and
ethnic distribution as well as comorbidities were similar
between groups, but there were more men in the inter-
vention group (Table 1). Therefore we adjusted for sex
in our analysis. Baseline TBMM, fat mass, and BMI
(Table 2) were similar in the intervention and control
groups. Patients’ average step counts were 18,579 (8,
865–37,219) steps/week or 2631 (1209 – 5239) steps/day
at baseline. Most patients’ median step counts classified
them as sedentary (< 5000 steps/day).
Change in outcomes at six months
Participants in the intervention group who had data available
for this BIS analysis increased average daily steps by 2414
more steps (95% CI 1047 to 3782) from 0 to 3months rela-
tive to controls, but during the 3months after the active
intervention phase decreased their step counts by 2429
(1016, 3841) compared to the control group. Therefore at 6
months there was no statistically significant difference in
change in average daily step count between intervention and
controls (49 steps, 95% CI − 1220 to 1317).
However, between 0 and 6months, TBMM increased
by 0.7 kg/m2 more in participants in the intervention
than in the control group (95% CI 0.3 to 1.3). Con-
versely, fat mass and BMI decreased by 4.3 kg (95% CI
1.5 to 7.1) and 1.0 kg/m2 (95% CI 0.2 to 1.8) more than
in the control group, respectively (Table 2). The effect of
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the intervention did not differ by modality (HD versus
PD) for any outcome (P for interaction > 0.9).
When examining individual time points, at 3months
TBMM for participants in the intervention had increased by
0.30 kg/m2 more than in the control group (− 0.1, 0.7) and
fat mass and BMI had decreased by − 1.7 kg (− 4.1, 0.8) and
− 0.2 kg/m2 (− 1.0, 0.6) more than in the control group, re-
spectively. However, no difference in change in body com-
position between 0 and 3months achieved statistical
significance. Between 3 and 6months, participants in the
intervention increased TBMM by 0.4 kg/m2 (95% CI 0.02 to
0.9), decreased fat mass by − 2.6 kg (95% CI − 5.3 to − 0.1),
and decreased BMI by − 0.8 kg/m2 (95% CI − 1.7 to − 0.01)
as compared to controls.
Post-hoc analysis of association of change in step counts
with change in body composition measures
When examining the entire study cohort, each increase
of 1000 steps per day from 0 to 3 months was associated
with a decline in fat mass of − 0.3 kg (95% CI − 0.5 to −
0.05) over the 6-month period of the study (Table 3).
There was no statistically significant association between
change in step count from 0 to 3 months and change in
TBMM or change in BMI.
Safety monitoring and adverse events
Of patients included in this analysis, six participants
(23.1%) reported symptoms related to the intervention.
Symptoms included shortness of breath (7.6%), soreness
(7.6%), lower extremity pain (3.8%), cramping (11.5%),
and fatigue during or after walking (7.6%). Two patients
reported chest pain with walking and were advised to
walk only as much as they usually would until they were
able to consult their cardiologists. One patient (in the
intervention group) died during the study, but the death
was determined not to be related to the intervention.
There were no hospitalizations related to the interven-
tion, nor was there any significant difference between
groups in hospitalizations within the last 6 months at
time of study completion.
Discussion
Participants in this study were sedentary when com-
pared to other studies of patients treated with dialysis
[20, 21] as well as studies measuring steps in other
chronic disease populations [15]. Participants in the
interventional group had a modest and statistically sig-
nificant increase in step counts from baseline to 3
months compared with controls but at 6 months had
Fig. 1 Recruitment, Randomization, and availability of BIS data
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Table 1 Patient characteristics at baseline for 44 hemodialysis patients and 10 peritoneal dialysis patientsa
Characteristic Control (N = 28) Intervention (N = 26)
Age, years 56 (51, 66) 59.5 (53, 66)
Sex, % male 61 92
Race and Ethnicity, %
White 18 15
Black 36 42
Asian 18 19
Hispanic 18 19
Other 14 15
Unknown/Unreported 11 8
BMI, kg/m2 31.6 (26.4, 34.6) 26.9 (25.3, 32.8)
Comorbidities, %
HTN 93 92
DM 43 38
CAD 25 35
CHF 25 27
Stroke 14 8
Peripheral Vascular Disease 4 14
HIV 4 0
Arrhythmia 11 15
Dialysis Vintage, years 2.1 (0.96, 5.21) 3.8 (1.6, 7.2)
Hemoglobin, g/dL 10.9 (9.9, 11.6) 10.6 (9.8, 11.7)
Serum Albumin, g/dL 3.9 (3.7, 4.1) 3.9 (3.6, 4.0)
Std Kt/V 2.39 (2.11, 2.52) 2.30 (2.07, 2.44)
Education, %
High School or Less 36 38
Vocational or Some College 32 27
College Degree 21 15
Professional or Graduate Degree 11 19
Currently smoking, % 36 15
aValues expressed in Median (25th, 75th percentile) or %
Table 2 Total body muscle mass (Adjusted for Height2), fat mass, and BMI in 44 hemodialysis patients and 10 peritoneal dialysis
patients
Baseline Difference in change
between groups from
baseline to 3 months
Difference in change
between groups from 3
to 6 monthsa
Difference in change
between groups from
baseline to 6 monthsa
Control (N = 28)
(25th, 75th
percentile)
Intervention
(N = 26)
(25th, 75th
percentile)
p-
value
Difference
(95% CI)
p
-value**
Difference
(95% CI)
p
-value**
Difference
(95% CI)
p
-value**
Total body muscle
mass/height2
(kg/m2)
10.3 (9.2, 11.4) 9.3 (8.3, 10.6) 0.65 0.3 (−0.1, 0.7) 0.14 0.4 (0.02, 0.9) 0.04 0.7 (0.3, 1.13) < 0.01
Fat mass (kg) 25.1 (16.8, 34.3) 23.1 (16.4, 32.2) 0.90 −1.7 (−4.1, 0.8) 0.18 −2.6 (−5.3, −
0.1)
0.04 − 4.3 (− 7.1, −
1.5)
< 0.01
BMI (kg/m2) 31.6 (26.7, 34.6) 26.9 (25.3, 32.8) 0.45 −0.2 (− 1.0,
0.6)
0.58 − 0.8 (− 1.7, −
0.01)
0.05 −1.0 (− 1.8, −
0.2)
0.02
aModeled through mixed-effects linear regression analysis
**p-value for between-group comparison of change, adjusted for sex and by stratification factor (modality)
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regressed back to baseline levels of walking. Despite
this regression, participants in the intervention group
had a significantly greater increase in TBMM, decrease
in fat mass, and decrease in BMI relative to controls
from 0 to 6 months (Fig. 2). There was a dose-response
relationship between steps added from 0 to 3 months
and loss in fat mass over the 6-month period of the
study but no similar relationship with TBMM or with
BMI. Weight loss appeared primarily driven by changes
in fat mass with relative preservation of muscle mass,
and the difference between groups was a combination
of improvement in the interventional group and nega-
tive changes in the control group.
Measurements of body mass tend to decline over time
in prevalent ESRD cohorts due in large part to the ef-
fects of malnutrition and inflammation [33, 34]. Having
higher muscle or lean body mass has been associated
consistently with survival benefits in patients with kidney
disease and particularly in those receiving dialysis [8, 9,
35]. Protein-energy wasting is itself an independent pre-
dictor of mortality and is associated with not only a loss
of lean body mass but also in increased fat mass. How-
ever, having a higher fat mass appears to be associated
with lower mortality in patients with kidney disease [35,
36]. Furthermore, loss of fat mass has been associated with
higher mortality in the dialysis population [37, 38], although
Table 3 Association of change in step count from baseline to 3 months with change in total body muscle mass, fat mass, and BMI
through linear regression analysis
Unadjusted Adjusteda
Change in total body
muscle mass/height2
(kg/m2)
Change in fat
mass (kg)
Change in
BMI
(kg/m2)
Change in total body
muscle mass/height2
(kg/m2)
Change in fat
mass (kg)
Change in
BMI
(kg/m2)
Change in average daily Step
Count (per 1000 steps)
0.01 (− 0.02, 0.05) −0.3 (− 0.6, −
0.1)
−0.04 (−
0.1, 0.03)
0.02 (− 0.02, 0.05) −0.3 (− 0.5, −
0.05)
−0.02 (−
0.1, 0.06)
p-value 0.44 < 0.01 0.28 0.39 0.02 0.57
aAdjusted for age, sex, and modality
Fig. 2 Body Composition in 44 HD and 10 PD patients at 0, 3, and 6 months
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it is not clear whether fat gain is protective. More recent
studies of discordant changes in muscle and fat mass show
that this “obesity paradox” may be explained more by
changes in muscle mass than fat mass [6], and having high
BMI with low muscle mass is associated with higher mortal-
ity than normal BMI with low muscle mass or high BMI
with high muscle mass [7]. It is possible that gain of muscle
mass with overall weight loss may confer additional survival
benefit over weight gain alone [36].
Our study shows that a walking intervention not only
prevented decline in muscle mass but also resulted in a
slight increase. Prior studies of moderate or vigorous re-
sistance exercise training in dialysis patients have shown
significant improvements in muscle mass [19, 22, 23], and
it may be that more vigorous exercise training results in
greater increase in muscle mass [39]. However, only a
fraction of dialysis patients are able to participate in such
interventions [40]. A walking program may be more man-
ageable, and if such an intervention were sustained for a
longer period of time, further improvement in muscle
mass may be possible. However, the fact that participants
in the intervention regressed in their step counts from 3
to 6months has important implications on the import-
ance of feedback to sustaining walking. If such an inter-
vention were scaled up, it may be necessary to implement
more automated or technology-driven methods to allow
for longer interventions without requiring weekly personal
contact. Our study also demonstrates a decrease in fat
mass in patients in the intervention group as compared to
an increase in fat mass in controls.
Although the between-group differences in change in BIS
measures at 6months appears to be driven at least as much
by decrease in muscle mass and increase in fat mass in the
controls, it is still surprising that total body muscle mass
continued to increase and fat mass continued to decrease in
the intervention group despite patients having regressed back
to baseline levels of walking at 6months. In fact, the
between-group differences in change in body composition
were larger from 3 to 6months than from 0 to 3months. It
may be that the intervention group continued to have higher
step counts for some portion of the follow-up period. How-
ever, as we did not measure weekly step counts in between
the 3- and 6-month assessments, we cannot ascertain whether
step counts immediately declined after study personnel ceased
providing feedback or whether participants were able to main-
tain their steps for a greater length of time. It is also possible
that the period of sustained exercise during the active portion
of the intervention resulted in a “legacy effect” sustained even
after patients’ step counts decreased back towards baseline
values. Though this type of effect has been described in other
studies of exercise, they have been more vigorous in intensity
and also of a longer duration [41]. However, the fact that the
number of steps gained in the intervention period was associ-
ated significantly with change in fat mass supports that the
initial ramp-up of activity played some role in the differences
in BIS measures at 6months. Inactivity is associated with
muscle atrophy [42], and the modest increase in steps during
the intervention period may have prevented wasting. Kidney
disease is also associated with a chronic inflammatory state
and significant protein-energy wasting [43–45], and physical
activity and exercise have been found to have anti-
inflammatory effects [46].
It should also be noted that step counts are a light-
intensity activity and do not capture the full spectrum of
physical activity. Therefore another possibility is that
though walking regressed from 3 to 6 months, patients
engaged in isotemporal substitution with other forms of
activity, and so some portion of the continued increase
in muscle mass and decrease in fat mass in the interven-
tion group was from reduction in overall sedentary time
rather than walking [47]. However, walking is the most
common form of physical activity for most dialysis pa-
tients [48], and it is not evident that patients would
switch their focus to other activities so readily. It is pos-
sible that activity of even low to moderate intensity
could result in reduced protein-energy wasting for a
period of time even after cessation of activity. Indeed,
sedentary behavior and protein-energy wasting have in-
dependent but synergistic effects on muscle [49].
This study has several limitations. We acknowledge that
more detailed information on the trajectory of step counts be-
tween 3 and 6months as well as data on other types of activity
that patients engaged in would be valuable in answering ques-
tions about the appropriate dose and duration of activity that
we should recommend to patients. Due to timing and patient
convenience, we performed measurements of BIS immediately
before hemodialysis when patients were not at their “dry”
weight. However, we did attempt to minimize variability by
performing all testing for hemodialyiss patients on a mid-
week dialysis day and at the same time prior to their sched-
uled dialysis sessions at all time points. In addition, the equa-
tion used to estimate total body muscle mass is derived from
pre-dialysis measurements of BIS [29]. Furthermore, our out-
come was the difference in change between groups. Study par-
ticipants were selected from dialysis facilities in the United
States, who may be more sedentary compared to patients
treated with dialysis elsewhere. However, it is not clear that
the baseline level of activity would affect the observed associ-
ation of increased walking with beneficial changes in body
composition. Finally, despite randomization, there were more
men in the interventional group. However, performing this
analysis as a difference in change between groups mitigates
the effect of any baseline imbalances.
Conclusions
Patients assigned to a pedometer-based intervention lost
weight compared with patients who did not engage in
the intervention, and this weight loss was driven
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primarily by reduction in fat mass with relative preserva-
tion of muscle mass. Achieved changes in step counts
were correlated with changes in fat mass. Walking inter-
ventions using simple and inexpensive devices such as
pedometers coupled with feedback on activity goals have
the potential to not only increase activity but also to re-
sult in beneficial changes in body composition. Further
study is needed to determine whether such changes can
be maintained over a longer duration or whether they
are of sufficient magnitude to result in improvement in
physical function or survival.
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